Hemogenyx Pharmaceuticals Shares Fall After FDA Puts Leukemia Treatment Application on Hold
June 02 2023 - 07:14AM
Dow Jones News
By Elena Vardon
Hemogenyx Pharmaceuticals shares slumped 28% on Friday after the
company said its application for its acute myeloid leukemia
treatment product candidate was put on clinical hold by the U.S.
Food and Drug Administration pending more information.
At 1034 GMT, shares were down 0.65 pence at 1.65 pence.
The biopharmaceutical group--that develops new therapies and
treatments for blood diseases--said its Investigational new drug
(IND) application for its chimeric antigen receptor t-cells is on
hold pending the receipt of a letter from the FDA.
The letter will set out additional information the FDA requires
from the company and is expected to be received within 30 days, it
said.
"We are confident that we will be able to address the FDA's
questions and concerns regarding the IND. [Acute myeloid leukemia]
has poor survival rates and we are eager to resolve this hold and
continue down the treatment development pathway toward saving
lives," Chief Executive Vladislav Sandler said.
Write to Elena Vardon at elena.vardon@wsj.com
(END) Dow Jones Newswires
June 02, 2023 06:59 ET (10:59 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Aug 2023 to Sep 2023
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Sep 2022 to Sep 2023